Pre-Conference Workshops & Engagers:
Wednesday, February 28, 2024
What's Next In the Future of Liquid Biopsy; featuring voices from the industry in partnership with Foundation Medicine
This workshop will cover:
- Strategic design using ctDNA monitoring in drug development
- Challenges in drug development with liquid biopsy
- Bringing liquid biopsy to global markets through trials and commercialisation including IDVR experiences, HGRAC approvals, tech transfer in France, and a Japan CDx story
Session Led By:
Troy Schurr, Chief Biopharma Business Officer Foundation Medicine
Amanda Young, Senior Director, Lifecycle Product Development Foundation Medicine
Tim Burns, Vice President Translational & Data Sciences, Tyra
Jean-Francois Martini, Executive Director, Translational Oncology Lead, Global Product Development, Pfizer
Flora Berisha, Global Head, Diagnostics Partnering & Development & Precision Medicine, Johnson & Johnson Innovative Medicines
Peter Krein, Vice President, Precision Medicine, Boundless Bio
1:00pm Afternoon Deep-Dive Workshop in Partnership with GRAIL
Beyond Genotyping & Tissue: Leveraging a Liquid Biopsy, Methylation-Based Platform
Across the Cancer Care Continuum
The need to determine whether pharma’s therapeutics will be effective in the right patients is critical to know at the earliest stages of development. GRAIL’s Methylation allows for a better representation of the activity of the tumour with an unbiased approach.
Learn how methylation can help with patient selection, monitoring and surveillance throughout the care continuum.
Opportunity to learn how methylation can be used to detect more aggressive tumours.
How to use methylation to address cancer at earlier stages than previously possible.
Using ML/AI infrastructure, knowhow and capabilities to optimise assay performance for many use cases.
Session Lead By:
Tyler Stewart, Assistant Professor, Department of Medicine UCSD
Bill Cance, Distinguished Scientist, Medical Affairs, GRAIL
Veerendra Munugalavadla, Senior Director, Translational Medicine, AstraZeneca
5:00pm Evening Thought Leadership Learn & Network Engager in Partnership with Guardant Health
Advancing Precision Oncology on A Global Scale by Bringing Liquid Biopsy Technology to New Regions
Access to liquid biopsy and genomic profiling varies significantly across regions, mostly due to regulatory hurdles and requirements. For pharma, when launching a new therapeutic, it’s critical to understand whether or not patients can be reliably identified for targeted therapies across regions.
Now, through our partnerships with Adicon, Royal Marsden, and Vall D’Hebron, Guardant is bringing our best-in-class CGP testing to global regions.
Through this Engager, Pharma can understand Guardant’s global capabilities which would inform their global launch strategies and/or regulatory submission strategies.
This evening thought leadership engager is a unique opportunity to learn through presentations, fire-side chats and an interactive Q&A session.
Session Lead By:
Naureen Starling The Royal Marsden
Melissa Gebhardt Senior Director, Business Development Guardant Health
Vafa Amirkia Director Business Development Guardant Health
Larry Wang CFO, SVP, Head of Business Development, Adicon